Close
Help
Need Help?



Forthcoming Articles 23 - 27 July 2012

Posted Thu, Jul, 26,2012

Libertas is pleased to announce that during the week of 23 - 27 July 2012 production commenced for the following articles:Bioinformatics and Biology InsightsBIONETWORK BENCH: Database and Software for Storage, Query, and Analysis of Gene and Protein NetworksCell Communication InsightsCell Communication Insights Redux: Passing of the TorchClinical Medicine Insights: TherapeuticsIntranasal fentanyl ...

Continue Reading →

Articles Published 23 - 27 July 2012

Posted Thu, Jul, 26,2012

These articles were published in the week of 23 - 27 July 2012:Biomarker InsightsMolecular Serum Markers of Liver FibrosisBreast Cancer: Basic and Clinical ResearchIdentification of Breast Cancer-Associated Lipids in Scalp HairRadiation-Triggered NF-κB Activation is Responsible for the Angiogenic Signaling Pathway and Neovascularization for Breast Cancer Cell Proliferation and GrowthCancer I...

Continue Reading →

Posted in: Articles Published

New Clinical Medicine Insights: Therapeutics Call for Papers

Posted Wed, Jul, 25,2012

The Editor in Chief, Dr Garry Walsh, is pleased to announce a new call for papers for Clinical Medicine Insights: Therapeutics. Submissions are being accepted now.All authors who submit their manuscripts to Libertas will benefit from:Convenient 3-step online manuscript submissionNo space restrictions or color figure chargesOptional immediate publicationInclusion of your article in: CAB Abstracts, ...

Continue Reading →

Posted in: Calls for Papers

Publish a Supplement in a Libertas Open Access Journal

Posted Wed, Jul, 25,2012

Following the substantial success of a recent supplement, which has been viewed more than 10,000 times since publication in January 2012, we announce our new supplement publication service.Libertas journals offer a high-visibility desination for supplements, combined with rapid processing and high author satisfaction.  Each supplement has a dedicated project manager to ensure prompt high-qual...

Continue Reading →

Promote Your Event or Conference

Posted Tue, Jul, 24,2012

Libertas journals now offer high visibility promotion for your academic conference, workshop or seminar.  Industry events and fairs are also considered.  Your event will be announced to the selected journal's large international audience of researchers and clinicians, using an attractive professional presentation.There is no charge for academic events, while industry events are subje...

Continue Reading →

Clinical Medicine Insights: Therapeutics Added to Gale Academic OneFile

Posted Mon, Jul, 23,2012

Libertas is pleased to announce that Clinical Medicine Insights: Therapeutics has now been added to Gale's Academic OneFile database.GALE operates more than 600 databases, including the popular InfoTrac and General Reference series. The Michigan based company is popular with authors working in the USA, so inclusion of Clinical Medicine Insights: Therapeutics in GALE's Academic OneFile will...

Continue Reading →

Our Service Promise

  • Prompt Processing (3 Weeks to Editorial Decision)
  • Fair, Independent Peer Review
  • High Visibility & Extensive Indexing
What Your Colleagues Say About Libertas Academica
I was delighted to submit an invited review on cluster headache pharmacology.  As someone who writes a few papers per year on these subjects, I appreciated that the submission, review and approval process for the paper was smooth and efficient. Our reviewers raised important points that improved the overall quality of the manuscript. Overall a very positive experience.
Dr Michael J. Marmura (Thomas Jefferson University, Philadelphia, PA, USA)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results